PR Newswire Clinical TrialsOriginal article
Cumulus Neuroscience Presents Data at AAIC 2026 Annual Meeting Showing a Two-Minute Digital Task Matches or Outperforms Clinical Benchmarks for Alzheimer's Trial Pre-enrichment
ConferencepositiveNeuLogiq® PlatformPositive
AI Analysis
Summary
Cumulus Neuroscience presented data at AAIC 2026 demonstrating that its NeuLogiq® Platform two-minute tablet-based Symbol Swap task matched or outperformed clinical benchmarks for Alzheimer's trial pre-enrichment, successfully discriminating between control, MCI, and Alzheimer's dementia groups across three independent studies.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Two-minute digital Symbol Swap task demonstrated clinically meaningful discrimination between control, MCI, and Alzheimer's dementia groups and detected blood-biomarker-defined pathology across three independent studies
Importance:5/10
Sentiment:
0.70
Alzheimer's diseaseBiomarkersDigital healthCognitive assessmentAAIC 2026Pre-enrichment
Read the original article
Published by PR Newswire Clinical Trials on July 15, 2026 9:11 AM